Drug Trial Radar · NCT06479759
LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jun 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Jan 12, 2024
Primary completion
Jun 12, 2025
Study completion Dec 12, 2025
Sponsor
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to investigate the efficacy, safety and tolerability of LM-108 antibody in combination with sintilimab for patients with locally advanced or metastatic Non-Small Cell Lung Cancer patients.
Conditions
- NSCLC
- PD-1
Interventions
LM-108 antibody and sintilimabDrug
Cohort 1 receive LM-108 monoclonal antibody combined with sintilimab
LM-108 antibody and sintilimab and chemotherapyDrug
Cohort 2 receive LM-108 monoclonal antibody combined with sintilimab and chemotherapy for 4-6 cycles. LM-108 monoclonal antibody combined with sintilimab will be maintained
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.